Financial Performance - Total revenue for Q1 2024 reached RMB 576,333,115.25, an increase of 26.4% compared to RMB 455,779,558.55 in Q1 2023[9] - The company's net profit for Q1 2024 reached ¥50,597,085.17, a significant increase from ¥22,037,147.18 in Q1 2023, representing a growth of approximately 130%[14] - Operating profit for the period was ¥66,663,340.33, compared to ¥28,440,895.40 in the same quarter last year, indicating an increase of about 134%[14] - Total revenue from sales of goods and services amounted to ¥694,754,702.08, up from ¥508,576,253.98 in Q1 2023, reflecting a growth of approximately 36.6%[17] - The total comprehensive income attributable to the parent company was ¥49,223,278.93, compared to ¥20,987,154.16 in Q1 2023, reflecting an increase of about 134%[15] - The net profit attributable to shareholders of the listed company was ¥49,223,278.93, a significant increase of 134.54% compared to the same period last year[44] Operating Costs and Expenses - Total operating costs for Q1 2024 were RMB 509,910,800.22, up from RMB 427,154,766.87 in Q1 2023, reflecting a 19.4% increase[9] - Research and development expenses increased to ¥5,831,085.27 from ¥3,183,767.55, showing a growth of approximately 83%[14] - The company’s financial expenses improved, with interest expenses recorded at ¥3,989,218.52, down from ¥144,000.00 in the previous year[14] Assets and Liabilities - The company's total assets amounted to RMB 2,650,434,736.29, compared to RMB 2,435,684,057.33 in the previous period, indicating a growth of 8.8%[4] - Total liabilities increased to RMB 1,271,542,815.53 from RMB 1,107,389,422.48, representing a rise of 14.8%[6] - Cash and cash equivalents at the end of the period totaled ¥798,763,621.12, up from ¥608,483,017.48 at the end of Q1 2023, indicating a growth of approximately 31.2%[22] - The equity attributable to shareholders of the listed company was ¥1,587,695,586.51, up 3.20% from the previous year-end[46] Cash Flow - The total cash flow from operating activities was ¥174,927,725.12, a substantial rise from ¥21,583,761.97 in the previous year[21] - The net cash flow from operating activities was ¥174,927,725.12, showing a remarkable increase of 710.46% year-on-year[44] - The company’s investment activities resulted in a net cash outflow of ¥198,159,457.69, compared to a smaller outflow of ¥7,959,268.53 in the previous year[21] Shareholder Information - The number of circulating shares held by the top shareholder, Wuhu Lian Tai Investment Management Center, is 180,509,529 shares[8] - The number of common shareholders at the end of the reporting period was 125,526[36] - The company has not reported any changes in the top 10 shareholders' participation in margin trading and securities lending[2] Earnings Per Share - The company reported a basic earnings per share of ¥0.0274 for Q1 2024, compared to ¥0.0117 in Q1 2023, marking an increase of 134%[15] - Basic earnings per share for Q1 2024 were ¥0.0274, reflecting a 134.19% increase compared to the previous year[44] Other Financial Information - The company has not identified any non-recurring gains or losses that are significant for this quarter[47] - Other non-operating income and expenses amounted to 792,644.12[54] - The income tax impact was 221,660.41[54] - The total non-recurring gains and losses after tax amounted to 570,983.72[54] - The company is not applying new accounting standards for the first time in 2024[3] - The weighted average return on equity for the quarter was 3.15%, an increase of 1.87 percentage points year-on-year[44] - The company reported a significant increase in sales scale and net profit margin during the reporting period[47] - Inventory decreased to RMB 89,939,743.57 from RMB 139,145,493.78, showing a reduction of 35.5%[4] - The company’s cash and cash equivalents increased to RMB 71,168,745.03 from RMB 59,529,147.22, a growth of 19.5%[4] - The company reported accounts receivable of RMB 111,927,013.70, an increase from RMB 103,455,360.81 in the previous period[4]
莲花健康(600186) - 2024 Q1 - 季度财报